Cold-responsive nanoparticle cryoimmunotherapy for reprogramming tumor microenvironment and boosting T cell immunity
Cold-responsive nanoparticles freeze tumors and deliver anticancer drugs and siRNA to trigger both tumor cell death and immune cell activation. Cytotoxic and memory T cells convert cold tumor environments into hot ones for a stronger, lasting anti-cancer response.
Background
Cancer immunotherapy harnesses the body’s immune system to recognize and eliminate tumor cells. Despite advances in checkpoint blockade and adoptive cell therapies, many solid tumors remain immunologically “cold,” with low infiltration of cytotoxic T cells and a dominant presence of suppressive regulatory cells. This immunosuppressive microenvironment prevents effective antitumor responses and contributes to disease progression and metastasis. There is therefore a pressing need for strategies that can reprogram the tumor milieu to support robust immune activation and durable systemic control of both primary and distant lesions.
Current approaches often rely on systemic administration of immune checkpoint inhibitors, conventional chemotherapy, or external radiation, each carrying significant limitations. Systemic therapies can cause off-target toxicity and immune-related adverse events, while failing to achieve sufficient drug concentration within dense tumor tissue. Physical and biological barriers within the tumor microenvironment, such as abnormal vasculature and a suppressive stroma, hinder effective delivery and activation of therapeutic agents. Moreover, many treatments trigger only transient immune responses, leaving residual tumor cells capable of evading detection and driving relapse. Addressing these shortcomings is critical to improving patient outcomes.
Technology
This technology uses cold-responsive nanoparticles to freeze tumors in place and then trigger the selective release of chemotherapy drugs and PD-L1 silencing siRNA directly into cancer cells. Upon administration, these nanoparticles accumulate in tumor tissue and respond to external cooling, causing localized frostbite that opens cell membranes. Simultaneously, they discharge anticancer drugs and the siRNA, leading to immunogenic cell death. The dying cells release signals that mature dendritic cells, which in turn activate CD8+ cytotoxic T cells and memory T cells, enhancing immune surveillance against both primary and metastatic tumors.
This approach sets itself apart by combining physical tumor disruption with precise molecular delivery to reshape the tumor microenvironment. Instead of relying solely on systemic drugs or immune checkpoint inhibitors, it converts immunologically “cold” tumors into “hot” ones by boosting the ratio of killer T cells to regulatory T cells. The cold-triggered nanoparticles provide tight control over when and where therapeutic agents are released, reducing off-target effects and inflammation. By provoking immediate tumor destruction while establishing long-lasting immune memory, this method tackles metastasis and lowers the chance of recurrence more effectively than traditional treatments.
Benefits
- Converts immunologically “cold” tumors into “hot” ones, enhancing anti-tumor immunity
- Increases the CD8+ cytotoxic T cell to regulatory T cell ratio in primary and distant tumors
- Targets cancer cells specifically via cold-responsive nanoparticles for precision treatment
- Rapidly releases anticancer drugs and PD-L1 silencing siRNA for combined chemo- and immunotherapy
- Induces immunogenic cell death, promoting dendritic cell maturation
- Activates and expands CD8+ cytotoxic and memory T cells for durable immune protection
- Reduces tumor metastasis by boosting systemic anti-tumor immune responses
Applications
- Targeted cancer immunotherapy
- Metastatic tumor treatment
- Nanoparticle drug delivery
- PD-L1 silencing therapy
- Localized cryo immunotherapy
Additional info
Cold-responsive nanoparticles target tumor cells, induce localized frostbite, and trigger rapid cytosolic release of chemotherapeutic agents and PD-L1–silencing siRNA. This generates immunogenic cell death, promotes dendritic cell maturation, elevates the CD8+/regulatory T cell ratio, and activates effector and memory T cells, converting the tumor microenvironment into a proinflammatory state and eliciting robust systemic antitumor immunity against both primary and metastatic lesions.
Publication
“In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy.” Ou, W., Stewart, S., White, A. et al. Nature Communications 14, 392 (2023).